Heat Biologics Stock News

T cell driven immune response achieved with just a single dosePotential to be used in combination with other COVID-19 vaccine approachesDURHAM, NC / ACCESSWIRE / August 13, 2020 / Heat Biologics, Inc.

Major new developments in the race for a COVID-19 vaccine are driving investors to reevaluate their positions.

Russia's surprise vaccine announcement isn't sitting well with shareholders of Dynavax, Heat Biologics, or Inovio Pharmaceuticals.

Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, tod

Opdivo Plus Yervoy Demonstrates Durable Survival Benefit vs. Chemotherapy in Patients with Previously Untreated Malignant Pleural Mesothelioma

* Progress on COVID-19 Vaccine Program * Reports over $100 million in cash and short-term investments as of August 6, 2020DURHAM, NC / ACCESSWIRE / August 7, 2020 / Heat Biologics, Inc.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces CStone Pharmaceuticals (“CStone”, HKEX: 2616) recently reported that its OmniAb-derived a

DS Announces Clinical Trial Collaboration with AZ to Evaluate Patritumab Deruxtecan (U3-1402) in Combination with TAGRISSO in EGFR-Mutated NSCLC

White paper highlights potential of Heat's vaccine to boost T cell immunity, alone or in combination with other vaccines DURHAM, NC / ACCESSWIRE / August 5, 2020 / Heat Biologics, Inc.

Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

Companies at the forefront of coronavirus vaccine research have been a veritable gold mine for investors this year. For example, shares of Moderna (NASDAQ: MRNA) have gained a staggering 278% over th

Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) („Takeda“) gab heute die Finanzergebnisse für das erste Quartal des Geschäftsjahres 2020 (